var data={"title":"Atropine (systemic): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Atropine (systemic): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/770531?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=atropine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Atropine (systemic): Drug information&quot;</a> and <a href=\"topic.htm?path=atropine-systemic-patient-drug-information\" class=\"drug drug_patient\">see &quot;Atropine (systemic): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406264\" class=\"block spa drugH1Div\"><span class=\"drugH1\">Special Alerts</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Pfizer Extended Expiration Dates for Emergency Syringe Shortages</span>\n      <span class=\"collapsible-date\">- updated November 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">The FDA has alerted health care providers of extended expiration dates for certain injectable drug products manufactured by Hospira (a Pfizer company) which may be used beyond the labeled expiration dates to assist with the ongoing critical shortages of injectable drugs used in critical care. Select lot numbers of atropine sulfate injection, dextrose 50%, epinephrine injection, and sodium bicarbonate are eligible for use beyond the labeled expiration date if they have been and will continue to be stored according to the labeled conditions<b>. </b></p>\n        <p style=\"text-indent:0em;\">Further information, including specific products, lot numbers, and extended expiration dates, may be found at <a target=\"_blank\" href=\"https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm&amp;token=8RYIFfyLhIBYEqeX7m6uPGtnB1wPEGG5AqBctyC78FXNni9GZNAqH+dg03OunIQVFis/VBQ2KMfj5sKJ1X0d3K8AtSQsFLDSFqHlsS1NKKs=&amp;TOPIC_ID=103678\" target=\"_blank\">https://www.fda.gov/Drugs/DrugSafety/DrugShortages/ucm563360.htm</a><b>.</b></p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">FDA Extends Expiration Dates for Certain Meridian Autoinjectors: Updated</span>\n      <span class=\"collapsible-date\">July 2017</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;margin-top:2em;\">The FDA is alerting health care providers and emergency responders that certain lots of <i>AtroPen</i> (atropine), <i>CANA</i> (diazepam), morphine sulfate, and pralidoxime chloride autoinjectors manufactured by Meridian Medical Technologies can be used beyond the labeled expiration date, which should help mitigate potential shortages of these drugs. To ensure patient safety, products should be stored under the manufacturer&rsquo;s labeled storage conditions.</p>\n        <p style=\"text-indent:0em;margin-top:2em;\">Additional information may be found at <a target=\"_blank\" href=\"http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm&amp;token=SHauxSdf9qNc6lLK16E8IDV3KxAgJ9eAUWFzIj8OhB+DS1QnG3nll2ktzEV1bFFqNvp/S6dk6auUFKQXeUZdHA==&amp;TOPIC_ID=103678\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm376367.htm</a>.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28564711\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>AtroPen</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625003\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antiasthmatic</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Anticholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antidote, Organophosphate Poisoning</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antispasmodic Agent, Gastrointestinal</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Bronchodilator</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F29135997\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bradycardia: Note:</b> Not part of neonatal resuscitation algorithm; some institutions have used the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, I.O.: 0.02 mg/kg/dose; use of a minimum dosage of 0.1 mg will result in dosages &gt;0.02 mg/kg and is not recommended (Barrington 2011); there is no documented minimum dosage in this age group; may repeat once in 3 to 5 minutes; reserve use for those patients unresponsive to improved oxygenation and epinephrine</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endotracheal: 0.04 to 0.06 mg/kg/dose; may repeat once if needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Intubation, nonemergent (preferred vagolytic):</b> IM, IV: 0.02 mg/kg/dose (Kumar 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Organophosphate or carbamate insecticide or nerve agent poisoning: Note:</b> The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV, IM: Initial: 0.05 to 0.1 mg/kg; repeat every 5 to 10 minutes as needed, doubling the dose if previous dose did not induce atropinization (Hegenbarth, 2008; Reigart, 1999; Rotenberg, 2003). Maintain atropinization by administering repeat doses as needed for &ge;2 to 12 hours based on recurrence of symptoms (Reigart 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous IV infusion: Following atropinization (see above), administer 10% to 20% of the total loading dose required to induce atropinization as a continuous IV infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (Eddleston 2004; Roberts 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: AtroPen: 0.25 mg (yellow pen):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mild symptoms (&ge;2 mild symptoms):</i> Administer one 0.25 mg (yellow pen) dose as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Severe symptoms (&ge;1 severe symptom):</i> Immediately administer <b>three</b> 0.25 mg (yellow pen) doses. Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary); <b>Note:</b> Neonates and infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endotracheal: Increase the dose by 2 to 3 times the usual IV dose. Mix with 3 to 5 mL of normal saline and administer. Flush with 3 to 5 mL of NS and follow with 5 assisted manual ventilations (Rotenberg 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625006\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=atropine-systemic-drug-information\" class=\"drug drug_general\">see &quot;Atropine (systemic): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bradycardia:</b> Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, I.O.: 0.02 mg/kg/dose; minimum dose recommended by PALS: 0.1 mg; however, use of a minimum dosage of 0.1 mg in patients &lt;5 kg will result in dosages &gt;0.02 mg/kg and is not recommended (Barrington 2011); there is no documented minimum dosage in this age group; maximum single dose: 0.5 mg; may repeat once in 3 to 5 minutes; maximum total dose: 1 mg (AHA 2015; PALS 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endotracheal: 0.04 to 0.06 mg/kg/dose; may repeat once if needed (AHA 2015; PALS 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Inhibit salivation and secretions (preanesthesia):</b> IM, IV, SubQ: Administer dose 30 to 60 minutes preoperatively then every 4 to 6 hours as needed:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing (Nelson 1996):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants weighing &lt;5 kg: 0.02 mg/kg/dose; use of a fixed minimum dosage of 0.1 mg will result in dosages &gt;0.02 mg/kg; there is no documented minimum dosage in this age group</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants weighing &ge;5 kg, Children, and Adolescents: 0.01 to 0.02 mg/kg/dose; maximum single dose: 0.4 mg; minimum dose: 0.1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Fixed dosing: Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">3 to 7 kg (7 to 16 lb): 0.1 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">8 to 11 kg (17 to 24 lb): 0.15 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">11 to 18 kg (24 to 40 lb): 0.2 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">18 to 29 kg (40 to 65 lb): 0.3 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;30 kg (&ge;65 lb): 0.4 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Intubation; emergent: Note:</b> Routine use not recommended for preintubation in infants and children; atropine may be considered in situations with a high-risk of bradycardia (eg, succinylcholine use) (PALS [deCaen 2015]) or septic shock (Brierley 2009). Infants and Children: IV: 0.02 mg/kg/dose; maximum single dose: 0.5 mg (PALS [deCaen 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Muscarine-containing mushroom poisoning:</b> Limited data available: Infants, Children, and Adolescents: IV: 0.02 mg/kg/dose; minimum dose: 0.1 mg. Titrate and repeat as needed (Goldfrank 2015)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Organophosphate or carbamate insecticide or nerve agent poisoning:</b> Infants, Children, and Adolescents: <b>Note:</b> The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to pralidoxime for the specific route and dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV, IM: Initial: 0.05 to 0.1 mg/kg; repeat every 5 to 10 minutes as needed, doubling the dose if previous dose does not induce atropinization (Hegenbarth 2008; Reigart 1999; Rotenberg 2003). Maintain atropinization by administering repeat doses as needed for &ge;2 to 12 hours based on recurrence of symptoms (Reigart 1999).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous IV infusion: Following atropinization, administer 10% to 20% of the total loading dose required to induce atropinization as a continuous IV infusion per hour; adjust as needed to maintain adequate atropinization without atropine toxicity (Eddleston 2004; Roberts 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM (AtroPen): Number of doses dependent upon symptom severity:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Weight-directed dosing:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&lt;6.8 kg (15 lb): 0.25 mg/dose (yellow pen)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">6.8 to 18 kg (15 to 40 lb): 0.5 mg/dose (blue pen)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">18 to 41 kg (40 to 90 lb): 1 mg/dose (dark red pen)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;41 kg (&gt;90 lb): 2 mg/dose (green pen)</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Mild symptoms (&ge;2 mild symptoms):</i> Administer the weight-based dose listed above as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Severe symptoms (&ge;1 severe symptom):</i> Immediately administer <b>three</b> weight-based doses in rapid succession. Symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary); <b>Note:</b> Infants may become drowsy or unconscious with muscle floppiness as opposed to muscle twitching.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endotracheal: Increase the dose by 2 to 3 times the usual IV dose. Mix with 3 to 5 mL of normal saline and administer. Flush with 3 to 5 mL of NS and follow with 5 assisted manual ventilations (Rotenberg 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> Doses &lt;0.5 mg have been associated with paradoxical bradycardia (Boudet 1991; L&ouml;nnerholm 1975):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Bradycardia:</b> IV: 0.5 mg every 3 to 5 minutes, not to exceed a total of 3 mg or 0.04 mg/kg (ACLS 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Neuromuscular blockade reversal:</b> IV: 15 to 30 mcg/kg administered with neostigmine or 7 to 10 mcg/kg administered with edrophonium (Cronnelly 1982; Miller 2010; Mirakhur 1981; Naguib 1989)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Organophosphate or carbamate insecticide or nerve agent poisoning: Note:</b> The dose of atropine required varies considerably with the severity of poisoning. The total amount of atropine used for carbamate poisoning is usually less than with organophosphate insecticide or nerve agent poisoning. Severely poisoned patients may exhibit significant tolerance to atropine; &ge;2 times the suggested doses may be needed. Titrate to pulmonary status (decreased bronchial secretions); consider administration of atropine via continuous IV infusion in patients requiring large doses of atropine. Once patient is stable for a period of time, the dose/dosing frequency may be decreased. Pralidoxime is a component of the management of organophosphate insecticide and nerve agent toxicity; refer to Pralidoxime monograph for the specific route and dose.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM (AtroPen):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Mild symptoms (&ge;2 mild symptoms):</i> Administer 2 mg as soon as an exposure is known or strongly suspected. If severe symptoms develop after the first dose, 2 additional doses should be repeated in rapid succession 10 minutes after the first dose; do not administer more than 3 doses. If profound anticholinergic effects occur in the absence of excessive bronchial secretions, further doses of atropine should be withheld. Mild symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy, include: Blurred vision, bradycardia, breathing difficulties, chest tightness, coughing, drooling, miosis, muscular twitching, nausea, runny nose, salivation increased, stomach cramps, tachycardia, teary eyes, tremor, vomiting, or wheezing.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Severe symptoms (&ge;1 severe symptom):</i> Immediately administer <b>three</b> 2 mg doses in rapid succession. Severe symptoms of insecticide or nerve agent poisoning, as provided by manufacturer in the AtroPen product labeling to guide therapy include: Breathing difficulties (severe), confused/strange behavior, defecation (involuntary), muscular twitching/generalized weakness (severe), respiratory secretions (severe), seizure, unconsciousness, urination (involuntary)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406340\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/mL (1 mL [DSC]); 1 mg/mL (1 mL); 8 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as sulfate [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.4 mg/0.5 mL (0.5 mL [DSC]); 0.4 mg/mL (1 mL); 1 mg/mL (1 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Auto-injector, Intramuscular, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AtroPen: 0.25 mg/0.3 mL (0.3 mL) [pyrogen free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">AtroPen: 0.5 mg/0.7 mL (0.7 mL); 1 mg/0.7 mL (0.7 mL); 2 mg/0.7 mL (0.7 mL) [pyrogen free; contains phenol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Injection, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 0.25 mg/5 mL (5 mL); 0.5 mg/5 mL (5 mL); 1 mg/10 mL (10 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Prefilled Syringe, Intravenous, as sulfate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2 mg/5 mL (5 mL [DSC]); 0.8 mg/2 mL (2 mL); 1 mg/2.5 mL (2.5 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406278\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406268\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">The AtroPen formulation is available for use primarily by the Department of Defense.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625008\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endotracheal: Administer and flush with 1 to 5 mL NS or SWFI based on patient size, followed by 5 manual ventilations. Absorption may be greater with sterile water. Stop compressions (if using for cardiac arrest), spray the drug quickly down the tube. Follow immediately with several quick insufflations and continue chest compressions. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IV: Administer undiluted by rapid IV injection; slow injection may result in paradoxical bradycardia </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">IM: AtroPen: Administer to the outer thigh. Firmly grasp the autoinjector with the green tip (0.5 mg, 1 mg, and 2 mg autoinjector) or black tip (0.25 mg autoinjector) pointed down; remove the yellow safety release (0.5 mg, 1 mg, and 2 mg autoinjector) or gray safety release (0.25 autoinjector). Firmly jab the green tip at a 90&deg; angle against the outer thigh; may be administered through clothing as long as pockets at the injection site are empty. In thin patients or patients &lt;6.8 kg (15 lb), bunch up the thigh prior to injection. Hold the autoinjector in place for 10 seconds following the injection; remove the autoinjector and massage the injection site. After administration, the needle will be visible; if the needle is not visible, repeat the above steps with more pressure. After use, bend the needle against a hard surface (needle does not retract) to avoid accidental injury. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406305\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">Store injection at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F); avoid freezing. In addition, AtroPen should be protected from light. Preparation of bulk atropine solution for mass chemical terrorism at a concentration of 1 mg/mL is stable for 72 hours at 4&deg;C to 8&deg;C (39&deg;F to 46&deg;F); 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F); 32&deg;C to 36&deg;C (90&deg;F to 97&deg;F) (Dix 2003). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625004\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Parenteral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Auto-injector: Antidote for anticholinesterase poisoning (carbamate insecticides, nerve agents, organophosphate insecticides, muscarinic poisoning) (FDA approved in all ages)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Injection: Preoperative medication to inhibit salivation and secretions; treatment of symptomatic sinus bradycardia, AV block (nodal level) adjuvant use with anticholinesterases (eg, edrophonium, neostigmine) to decrease their side effects during reversal of neuromuscular blockade [All indications: FDA approved in pediatric patients (age not specified) and adults]; <b>Note:</b> Use is no longer recommended in the management of asystole or pulseless electrical activity (PEA) (ACLS 2010)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28564710\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Geriatric Patients: High-Risk Medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Beers Criteria: Atropine is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older (independent of diagnosis or condition) due to its highly anticholinergic properties and uncertain effectiveness as an antispasmodic (Beers Criteria [AGS 2015]).</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406295\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Severity and frequency of adverse reactions are dose related.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Asystole, atrial arrhythmia, atrial fibrillation, atrioventricular dissociation (transient), bigeminy, bradycardia, chest pain, decreased blood pressure, ECG changes (prolonged P wave, shortened PR segment, R on T phenomenon, shortened RT duration, prolonged QT interval, widening of QRS Complex, flattened T wave, repolarization abnormalities, ST segment elevation, retrograde conduction), ectopic beats (atrial), extrasystoles (nodal, ventricular, superventricular), flushing, increased blood pressure, left heart failure, myocardial infarction, nodal arrhythmia (no P wave on ECG), palpitations, sinus tachycardia, supraventricular tachycardia (including junctional tachycardia), tachycardia, trigeminy, ventricular arrhythmia (including flutter), ventricular fibrillation, ventricular flutter, ventricular premature contractions, ventricular tachycardia, weak pulse (or impalpable peripheral pulses)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal electroencephalogram (runs of alpha waves, increase in photic stimulation, and signs of drowsiness), agitation (children), amnesia, anxiety, ataxia, behavioral changes, coma, confusion, decreased deep tendon reflex, delirium, dizziness, drowsiness, dysarthria, dysmetria, emotional disturbance, excitement, feeling hot, hallucination (visual or aural), headache, hyperpyrexia, hyperreflexia, hypertonia, insomnia, intoxicated feeling, irritability (children), lack of concentration, lethargy (children), mania, myoclonus, neurologic abnormality, nocturnal enuresis, opisthotonus, paranoia, positive Babinski sign, restlessness, seizure (generally tonic-clonic), stupor, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Anhidrosis, cold skin, dermatitis, dry and hot skin, erythematous rash, hyperhidrosis, macular eruption, maculopapular rash, papular rash, scarlatiniform rash, skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Dehydration, hyperglycemia, hypoglycemia, hypokalemia, hyponatremia, increased thirst, loss of libido</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal and bladder distension, abdominal pain, constipation, delayed gastric emptying, diminished bowel sounds, dry mucous membranes, dysphagia, malabsorption, nausea, oral lesion, paralytic ileus, salivation, vomiting, xerostomia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Difficulty in micturition, impotence, urinary hesitancy, urinary retention, urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Abnormal erythrocytes (increased), decreased hemoglobin, increased hemoglobin, leukocytosis, petechiae</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Injection site reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Laryngospasm, muscle twitching, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Abnormal eye movements (cyclophoria and heterophoria), angle-closure glaucoma (acute), blepharitis, blindness, blurred vision, conjunctivitis, crusted of eyelid, cycloplegia, decreased accommodation, decreased visual acuity, dry eye syndrome, eye irritation, keratoconjunctivitis sicca, lacrimation, mydriasis, photophobia, strabismus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased blood urea nitrogen</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Bradypnea, changes in respiration (labored respiration), cyanosis, dyspnea, laryngitis, pulmonary edema, respiratory failure, stridor (inspiratory), tachypnea</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Failure to thrive, fever (secondary to decreased sweat gland activity), swelling (children)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406290\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406291\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthermia: In the presence of a high environmental temperature, heat prostration can occur.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychosis: Can occur in sensitive individuals or following use of excessive doses.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Urinary retention: Avoid use if possible in patients with obstructive uropathy or in other conditions resulting in urinary retention; use may lead to complete urinary retention in patients with prostatic hypertrophy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticholinesterase poisoning: Atropine reverses the muscarinic but not the nicotinic effects associated with anticholinesterase toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Arrhythmias: Avoid relying on atropine for effective treatment of type II second-degree or third-degree AV block (with or without a new wide QRS complex). Asystole or bradycardic PEA: Although no evidence exists for significant detrimental effects, routine use is unlikely to have a therapeutic benefit and is no longer recommended (ACLS, 2010).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Autonomic neuropathy: Use with caution in patients with autonomic neuropathy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disease: Use with caution in patients with myocardial ischemia, HF, tachyarrhythmias (including sinus tachycardia), and/or hypertension; treatment-related blood pressure increases and tachycardia may lead to ischemia, precipitate an MI, or increase arrhythmogenic potential.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal disease: Avoid use in patients with paralytic ileus, intestinal atony of the elderly or debilitated patient, severe ulcerative colitis, and toxic megacolon complicating ulcerative colitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution in patients with hepatic impairment; effects of atropine may be prolonged in severe hepatic impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hiatal hernia: Use with caution in patients with hiatal hernia associated with reflux esophagitis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperthyroidism: Use with caution in patients with hyperthyroidism.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myasthenia gravis: In patients with myasthenia gravis, use atropine with extreme caution when used to treat side effects of acetylcholinesterase inhibition or avoid; may precipitate a myasthenic crisis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment; effects of atropine may be prolonged in severe renal impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart transplant recipients: Atropine will likely be ineffective in treatment of bradycardia due to lack of vagal innervation of the transplanted heart. Cholinergic reinnervation may occur over time (years), so atropine may be used cautiously; however, some may experience paradoxical slowing of the heart rate and high-degree AV block upon administration (ACLS, 2010; Bernheim, 2004).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Children may be more sensitive to the anticholinergic effects of atropine. Use with caution in children with spastic paralysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions: </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Anticholinesterase poisoning: Clinical symptoms consistent with highly-suspected organophosphate or carbamate insecticides or nerve agent poisoning should be treated with antidote immediately; administration should not be delayed for confirmatory laboratory tests. Signs of atropinization include flushing, mydriasis, tachycardia, and dryness of the mouth or nose. Monitor effects closely when administering subsequent injections as necessary. The presence of these effects is not indicative of the success of therapy; inappropriate use of mydriasis as an indicator of successful treatment has resulted in atropine toxicity. Reversal of bronchial secretions is the preferred indicator of success. Adjunct treatment with a cholinesterase reactivator (eg, pralidoxime) may be required in patients with toxicity secondary to organophosphorus insecticides or nerve agents. Treatment should always include proper evacuation and decontamination procedures; medical personnel should protect themselves from inadvertent contamination. Antidotal administration is intended only for initial management; definitive and more extensive medical care is required following administration. Individuals should not rely solely on antidote for treatment, as other supportive measures (eg, artificial respiration) may still be required.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406300\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406297\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=103678&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Acetylcholinesterase Inhibitors: May diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amezinium: Atropine (Systemic) may enhance the stimulatory effect of Amezinium. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: May diminish the anticholinergic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Amifampridine.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the adverse/toxic effect of other Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoid-Containing Products. <b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloral Betaine: May enhance the adverse/toxic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cimetropium: Anticholinergic Agents may enhance the anticholinergic effect of Cimetropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eluxadoline: Anticholinergic Agents may enhance the constipating effect of Eluxadoline. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">EPHEDrine (Systemic): Atropine (Systemic) may enhance the therapeutic effect of EPHEDrine (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal Agents (Prokinetic): Anticholinergic Agents may diminish the therapeutic effect of Gastrointestinal Agents (Prokinetic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glucagon: Anticholinergic Agents may enhance the adverse/toxic effect of Glucagon. Specifically, the risk of gastrointestinal adverse effects may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Glycopyrrolate (Oral Inhalation): Anticholinergic Agents may enhance the anticholinergic effect of Glycopyrrolate (Oral Inhalation). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Itopride: Anticholinergic Agents may diminish the therapeutic effect of Itopride. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levosulpiride: Anticholinergic Agents may diminish the therapeutic effect of Levosulpiride. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Macimorelin: Atropine (Systemic) may diminish the diagnostic effect of Macimorelin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mianserin: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mirabegron: Anticholinergic Agents may enhance the adverse/toxic effect of Mirabegron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroglycerin: Anticholinergic Agents may decrease the absorption of Nitroglycerin. Specifically, anticholinergic agents may decrease the dissolution of sublingual nitroglycerin tablets, possibly impairing or slowing nitroglycerin absorption. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Opioid Analgesics: Anticholinergic Agents may enhance the adverse/toxic effect of Opioid Analgesics. Specifically, the risk for constipation and urinary retention may be increased with this combination. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oxatomide: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Citrate: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Citrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pramlintide: May enhance the anticholinergic effect of Anticholinergic Agents. These effects are specific to the GI tract.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ramosetron: Anticholinergic Agents may enhance the constipating effect of Ramosetron. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritodrine: Atropine (Systemic) may enhance the adverse/toxic effect of Ritodrine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.  Management: Avoid concomitant use of anticholinergic agents and secretin. Discontinue anticholinergic agents at least 5 half-lives prior to administration of secretin.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thiazide and Thiazide-Like Diuretics: Anticholinergic Agents may increase the serum concentration of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tiotropium: Anticholinergic Agents may enhance the anticholinergic effect of Tiotropium. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Umeclidinium: May enhance the anticholinergic effect of Anticholinergic Agents.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406286\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B/C (manufacturer specific) (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406287\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies (studies not conducted by all manufacturers). Atropine has been found to cross the human placenta (Kanto 1981). In general, medications used as antidotes should take into consideration the health and prognosis of the mother; antidotes should be administered to pregnant women if there is a clear indication for use and should not be withheld because of fears of teratogenicity (Bailey 2003). Medications used for the treatment of cardiac arrest in pregnancy are the same as in the non-pregnant woman. Doses and indications should follow current Advanced Cardiovascular Life Support guidelines. Appropriate medications should not be withheld due to concerns of fetal teratogenicity (Jeejeebhoy [AHA] 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28625009\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Heart rate, blood pressure, pulse, mental status; intravenous administration requires a cardiac monitor</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <i>Organophosphate or carbamate insecticide or nerve agent poisoning:</i> Heart rate, blood pressure, respiratory status, oxygenation secretions. Maintain atropinization with repeated dosing as indicated by clinical status. Crackles in lung bases, or continuation of cholinergic signs, may be signs of inadequate dosing. Pulmonary improvement may not parallel other signs of atropinization. Monitor for signs and symptoms of atropine toxicity (eg, fever, muscle fasciculations, delirium); if toxicity occurs, discontinue atropine and monitor closely.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Consult individual institutional policies and procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406309\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Blocks the action of acetylcholine at parasympathetic sites in smooth muscle, secretory glands, and the CNS; increases cardiac output, dries secretions. Atropine reverses the muscarinic effects of cholinergic poisoning due to agents with acetylcholinesterase inhibitor activity by acting as a competitive antagonist of acetylcholine at muscarinic receptors. The primary goal in cholinergic poisonings is reversal of bronchorrhea and bronchoconstriction. Atropine has no effect on the nicotinic receptors responsible for muscle weakness, fasciculations, and paralysis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406311\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Inhibition of salivation: IM: Within 30 minutes; maximum effect: 30 to 60 minutes (Mirakhur 1980; Volz-Zang 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Increased heart rate:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IM: Within 15 to 30 minutes (Kentala 1990; Volz-Zang 1995); maximum effect: 45 to 60 minutes (Mirakhur 1980; Volz-Zang 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">IV: Immediate; maximum effect: 0.7 to 4 minutes (Lonnerholm 1975; Santini 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: Inhibition of salivation: IM: &le;4 hours (Mirakhur 1980; Volz-Zang 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Rapid and well absorbed from all dosage forms </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Widely throughout the body; crosses blood-brain barrier </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 14% to 22% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic via enzymatic hydrolysis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Children &lt;2 years: 6.9 &plusmn; 3 hours; Children &gt;2 years: 2.5 &plusmn; 1.2 hours; Adults: 3 &plusmn; 0.9 hours; Elderly 65 to 75 years of age: 10 &plusmn; 7.3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Time to peak: IM: Autoinjector: 3 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (13% to 50% as unchanged drug and metabolites)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F28406343\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Atropine Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.4 mg/mL (1 mL): $8.75</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/mL (1 mL): $1.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8 mg/20 mL (20 mL): $2.88</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Auto-injector</b> (AtroPen Intramuscular)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/0.3 mL (0.3 mL): $36.28</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/0.7 mL (0.7 mL): $30.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/0.7 mL (0.7 mL): $30.36</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2 mg/0.7 mL (0.7 mL): $30.36</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Atropine Sulfate Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25 mg/5 mL (5 mL): $15.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.5 mg/5 mL (5 mL): $9.96</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/10 mL (10 mL): $10.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution Prefilled Syringe</b> (Atropine Sulfate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.8 mg/2 mL (2 mL): $9.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 mg/2.5 mL (2.5 mL): $11.51</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30124630\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anespin (PH);</li>\n      <li>Atren (IN);</li>\n      <li>Atro (IN);</li>\n      <li>Atropa (LK);</li>\n      <li>Atropan (PH);</li>\n      <li>Atropin (SE);</li>\n      <li>Atropin Biotika (CZ);</li>\n      <li>Atropion (BR);</li>\n      <li>Atrosol (PK);</li>\n      <li>Bellafit (FR);</li>\n      <li>Bellafit N (CH);</li>\n      <li>Cholspas Atropin (DE);</li>\n      <li>Ciratro (LK);</li>\n      <li>Darnytsya (UA);</li>\n      <li>Dysurgal (DE);</li>\n      <li>Endotropina (AR, UY);</li>\n      <li>Estropin (BD);</li>\n      <li>Santropina (BR);</li>\n      <li>Stellatropine (BE);</li>\n      <li>Tropyn (MX)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    American Heart Association (AHA). 2015 <i>Handbook of Emergency Cardiovascular Care (ECC) for Healthcare Providers</i>. First American Heart Association Printing. November 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Andriessen P, Janssen BJ, Berendsen RC, et al. Cardiovascular autonomic regulation in preterm infants: the effect of atropine. <i>Pediatr Res</i>. 2004; 56(6):939-946.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15470200 /pubmed\" target=\"_blank\" id=\"15470200 \">15470200 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atropine sulfate [prescribing information]. Eatontown, NJ: West-Ward Pharmaceuticals; July 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atropine sulfate [prescribing information]. El Monte, CA: International Medication Systems, Limited; August 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atropine sulfate [prescribing information]. Lake Forest, IL: Hospira, Inc; November 2004.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bailey B. Are there teratogenic risks associated with antidotes used in the acute management of poisoned pregnant women? <i>Birth Defects Res A Clin Mol Teratol</i>. 2003;67(2):133-140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12769509/pubmed\" target=\"_blank\" id=\"12769509\">12769509</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Barrington KJ, &quot;The Myth of a Minimum Dose for Atropine,&quot; <i>Pediatrics</i>, 2011, 127(4):783-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/21382950/pubmed\" target=\"_blank\" id=\"21382950\">21382950</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bernheim A, Fatio R, Kiowski W, et al, &ldquo;Atropine Often Results in Complete Atrioventricular Block or Sinus Arrest After Cardiac Transplantation: An Unpredictable and Dose-Independent Phenomenon,&rdquo; <i>Transplantation</i>, 2004, 77(8):1181-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15114081/pubmed\" target=\"_blank\" id=\"15114081\">15114081</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Boudet J, Qing W, Boyer-Chammard A, et al. Dose-response effects of atropine in human volunteers. <i>Fundam Clin Pharmacol</i>. 1991;5(7):635-640.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/1778541/pubmed\" target=\"_blank\" id=\"1778541\">1778541</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brierley J, Carcillo JA, Choong K, et al. Clinical practice parameters for hemodynamic support of pediatric and neonatal septic shock: 2007 update from the American College of Critical Care Medicine. <i>Crit Care Med</i>. 2009;37(2):666-688.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/19325359/pubmed\" target=\"_blank\" id=\"19325359\">19325359</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cronnelly R, Morris RB, Miller RD. Edrophonium: duration of action and atropine requirement in humans during halothane anesthesia. <i>Anesthesiology</i>. 1982;57(4):261-266.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7125261/pubmed\" target=\"_blank\" id=\"7125261\">7125261</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care (Reprint). <i>Pediatrics</i>. 2015;136(Suppl 2:)S176-195.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26471384/pubmed\" target=\"_blank\" id=\"26471384\">26471384</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dempsey EM, Al Hazzani F, Faucher D, et al. Facilitation of neonatal endotracheal intubation with mivacurium and fentanyl in the neonatal intensive care unit. <i>Arch Dis Child Fetal Neonatal Ed</i>. 2006; 91(4):F279-282.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/16464937 /pubmed\" target=\"_blank\" id=\"16464937 \">16464937 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dix J, Weber RJ, Frye RF, et al, &ldquo;Stability of Atropine Sulfate Prepared for Mass Chemical Terrorism,&rdquo; <i>J Toxicol Clin Toxicol</i>, 2003, 41(6):771-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/14677786/pubmed\" target=\"_blank\" id=\"14677786\">14677786</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eddleston M, Dawson A, Karalliedde L, et al, &ldquo;Early Management After Self-Poisoning with an Organophosphorus or Carbamate Pesticide &ndash; A Treatment Protocol for Junior Doctors,&rdquo; <i>Crit Care</i>, 2004b, 8(6):R391-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/15566582/pubmed\" target=\"_blank\" id=\"15566582\">15566582</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Field JM, Hazinski MF, Sayre MR, et al, &ldquo;Part 1: Executive Summary: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122 (Suppl 3):640-56.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Goldfrank RS, Howland MA, Lewing NA, Nelson LS, Goldfrank LS, eds. <i>Goldfrank's Toxocologic Emergencies</i>. 10th ed. McGraw Hill Education. 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hegenbarth MA, &ldquo;Preparing for Pediatric Emergencies: Drugs to Consider,&rdquo; <i>Pediatrics</i>, 2008, 121(2):433-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/18245435/pubmed\" target=\"_blank\" id=\"18245435\">18245435</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeejeebhoy FM, Zelop CM, Lipman S, et al; American Heart Association Emergency Cardiovascular Care Committee, Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation, Council on Cardiovascular Diseases in the Young, and Council on Clinical Cardiology. Cardiac Arrest in Pregnancy: A Scientific Statement From the American Heart Association. <i>Circulation</i>. 2015;132(18):1747-1773. doi: 10.1161/CIR.0000000000000300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/26443610/pubmed\" target=\"_blank\" id=\"26443610\">26443610</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kanto J, Virtanen R, Iisalo E, et al, &quot;Placental Transfer and Pharmacokinetics of Atropine After a Single Maternal Intravenous and Intramuscular Administration,&quot; <i>Acta Anaesthesiol Scand</i>, 1981, 25(2):85-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7324829/pubmed\" target=\"_blank\" id=\"7324829\">7324829</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kentala E, Kaila T, Iisalo E, Kanto J. Intramuscular atropine in healthy volunteers: a pharmacokinetic and pharmacodynamic study. <i>Int J Clin Pharmacol Ther Toxicol</i>. 1990;28(9):399-404.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/2228327/pubmed\" target=\"_blank\" id=\"2228327\">2228327</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleinman ME, Chameides L, Schexnayder SM, et al, &ldquo;Part 14: Pediatric Advanced Life Support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care,&rdquo; <i>Circulation</i>, 2010, 122(18 Suppl 3):876-908.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/20956230/pubmed\" target=\"_blank\" id=\"20956230\">20956230</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kumar P, Denson SE, Mancuso TJ, et al. Premedication for nonemergency endotracheal intubation in the neonate. <i>Pediatrics</i>. 2010; 125(3):608-615.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    L&ouml;nnerholm G, Widerl&ouml;v E. Effect of intravenous atropine and methylatropine on heart rate and secretion of saliva in man. <i>Eur J Clin Pharmacol</i>. 1975;8(3-4):233-240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/786681/pubmed\" target=\"_blank\" id=\"786681\">786681</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Miller RD, ed. <i>Miller's Anesthesia</i>. 7th ed. Philadelphia PA: Churchill Livingstone; 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mirakhur RK, Dundee JW, Jones CJ, Coppel DL, Clarke RS. Reversal of neuromuscular blockade: dose determination studies with atropine and glycopyrrolate given before or in a mixture with neostigmine. <i>Anesth Analg</i>. 1981;60(8):557-562.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/7196168/pubmed\" target=\"_blank\" id=\"7196168\">7196168</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Naguib M, Gomaa M. Atropine-neostigmine mixture: a dose-response study. <i>Can J Anaesth</i>. 1989;36(4):412-417.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/2758540/pubmed\" target=\"_blank\" id=\"2758540\">2758540</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nelson WE, Behrman RE, Kliegman RM, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 15th ed. Philadelphia, PA: WB Saunders Company; 1996.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Neumar RW, Otto CW, Link MS, et al, &quot;Part 8: adult advanced cardiovascular life support (ACLS): 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care.<i> Circulation</i>. 2010; 122(18 Suppl 3):S729-767.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/20956224/pubmed\" target=\"_blank\" id=\"20956224\">20956224</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oei J, Hari R, Butha T, Lui K. Facilitation of neonatal nasotracheal intubation with premedication: a randomized controlled trial. <i>J Paediatr Child Health</i>. 2002;38(2):146-150.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12030995 /pubmed\" target=\"_blank\" id=\"12030995 \">12030995 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reigart JR and Roberts JR, &ldquo;Recognition and Management of Pesticide Poisonings,&rdquo; U.S. Environmental Protection Agency, Washington, D.C., 5th edition, 1999: 34-47. Available at <a href=\"http://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm\" target=\"_blank\">http://www.epa.gov/oppfead1/safety/healthcare/handbook/handbook.htm</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts DM and Aaron CK, &ldquo;Management of Acute Organophosphorus Pesticide Poisoning,&rdquo; <i>BMJ</i>, 2007, 334(7594):629-34.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/17379909/pubmed\" target=\"_blank\" id=\"17379909\">17379909</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roberts KD, Leone TA, Edwards WH, et al. Premedication for nonemergent neonatal intubations: a randomized, controlled trial comparing atropine and fentanyl to atropine, fentanyl, and mivacurium. <i>Pediatrics</i>. 2006; 118(4):1583-1591.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/17015550 /pubmed\" target=\"_blank\" id=\"17015550 \">17015550 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rotenberg JS and Newmark J, &quot;Nerve Agent Attacks on Children: Diagnosis and Management,&quot; <i>Pediatrics</i>, 2003, 112(3 Pt 1):648-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/12949297/pubmed\" target=\"_blank\" id=\"12949297\">12949297</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santini M, Ammirati F, Colivicchi F, Gentilucci G, Guido V. The effect of atropine in vasovagal syncope induced by head-up tilt testing. <i>Eur Heart J</i>. 1999;20(23):1745-1751.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/10562483/pubmed\" target=\"_blank\" id=\"10562483\">10562483</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Volz-Zang C, Waldh&auml;user T, Schulte B, Palm D. Comparison of the effects of atropine in vivo and ex vivo (radioreceptor assay) after oral and intramuscular administration to man. <i>Eur J Clin Pharmacol</i>. 1995;49(1-2):45-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/atropine-systemic-pediatric-drug-information/abstract-text/8751020/pubmed\" target=\"_blank\" id=\"8751020\">8751020</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 103678 Version 70.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Special Alerts\" href=\"#F28406264\" class=\"outlineLink\">Special Alerts</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F28564711\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F28625003\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F29135997\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F28625006\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F28406340\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F28406278\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F28406268\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F28625008\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F28406305\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F28625004\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F28564710\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F28406295\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F28406290\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F28406291\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F28406300\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F28406297\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F28406286\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F28406287\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F28625009\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F28406309\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F28406311\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F28406343\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F30124630\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/103678|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=atropine-systemic-drug-information\" class=\"drug drug_general\">Atropine (systemic): Drug information</a></li><li><a href=\"topic.htm?path=atropine-systemic-patient-drug-information\" class=\"drug drug_patient\">Atropine (systemic): Patient drug information</a></li></ul></div></div>","javascript":null}